SciELO - Scientific Electronic Library Online

vol.47 issue1Drugs and clinical trials in neurodegenerative diseasesThe dawn of mesoscopic approach in drug development author indexsubject indexarticles search
Home Page  

Services on Demand




Related links

  • Have no similar articlesSimilars in SciELO


Annali dell'Istituto Superiore di Sanità

Print version ISSN 0021-2571


PUOPOLO, Maria  and  POCCHIARI, Maurizio. Need to improve clinical trials in rare neurodegenerative disorders. Ann. Ist. Super. Sanità [online]. 2011, vol.47, n.1, pp.55-59. ISSN 0021-2571.

Rare neurodegenerative diseases are fatal and no therapy is available to cure or slow down the progression of disease. We report possibly weaknesses in the management of clinical studies in these diseases, ranging from poor preclinical studies, difficulties in the recruitment of patients, delay in the onset of treatment because of lack in early disease-specific biomarkers, and suboptimal design of Phase II clinical trials. The adoption of innovative statistical approaches in early Phase II trials might improve the screening of drugs in rare neurodegenerative disorders, but this implicates efforts from clinical researchers, statisticians, and regulatory people to the development of new strategies that should maintain rigorous scientific integrity together with a more ethical approach to human experimentations.

Keywords : clinical trials; neurodegenerative diseases.

        · abstract in Italian     · text in English     · English ( pdf )